In conclusion, our results provided evidences for the predictive role of XPD Asp312Asn, Asp711Asp and Lys751Gln polymorphisms/haplotype on NSCLC prognosis among NSCLC patients treated with platinum-based chemotherapy, which suggested that these XPD polymorphisms might be used in risk assessment for chemotherapy effect prediction and individualized treatment optimization. The gene discussed is ERCC2; the disease is non-small cell lung carcinoma.